Mankind Pharma Sees Sharp Open Interest Surge Signalling Bullish Market Positioning

Open Interest and Volume Dynamics

On 23 June 2026, Mankind Pharma’s open interest in futures and options contracts rose sharply by 2,760 contracts, an 11.87% increase from the previous day’s 23,247 to 26,007. This notable expansion in OI was accompanied by a robust trading volume of 18,951 contracts, underscoring active participation from market participants. The futures segment alone accounted for a value of approximately ₹6,192.13 lakhs, while the options segment’s notional value stood at an impressive ₹10,533.14 crores, culminating in a total derivatives value of ₹7,547.89 lakhs.

Such a pronounced rise in open interest, alongside elevated volumes, typically signals fresh capital inflows and new directional bets rather than mere position unwinding. This pattern suggests that traders are increasingly positioning themselves for a continuation of the stock’s upward momentum.

Price Performance and Technical Strength

Mankind Pharma’s underlying share price closed at ₹2,587 on the day, just 4.99% shy of its 52-week high of ₹2,716.50. The stock has been on a consistent upward trajectory, registering gains for five consecutive trading sessions and delivering a cumulative return of 9.82% during this period. Intraday, the stock touched a high of ₹2,589.10, marking a 2% rise from the previous close.

Technically, the stock is trading above all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — indicating a strong bullish trend across multiple timeframes. This technical strength is further supported by a surge in delivery volume, which on 22 June reached 4.54 lakh shares, a remarkable 110.27% increase compared to the five-day average delivery volume. Such rising investor participation through delivery volumes points to genuine accumulation rather than speculative trading.

Market Capitalisation and Sector Context

Mankind Pharma is classified as a mid-cap company with a market capitalisation of ₹1,04,779 crores. Operating within the Pharmaceuticals & Biotechnology sector, the stock outperformed its sector peers on the day, registering a 2.10% gain compared to the sector’s 1.74% rise and the Sensex’s marginal 0.06% increase. This relative outperformance highlights the stock’s growing appeal amid a broadly positive sectoral backdrop.

Implications of Rising Open Interest

The surge in open interest, combined with rising volumes and price appreciation, typically indicates that new long positions are being established. This suggests that market participants are betting on further upside in Mankind Pharma’s stock price. The increase in futures value to ₹6,192.13 lakhs and the substantial options notional value reinforce the notion of heightened speculative and hedging activity.

Given the stock’s proximity to its 52-week high and strong technical indicators, the market positioning appears to favour a bullish outlook. Investors and traders are likely anticipating positive catalysts, possibly linked to the company’s robust fundamentals, sector tailwinds, or upcoming corporate developments.

Mojo Score Upgrade and Analyst Sentiment

Reflecting this positive momentum, Mankind Pharma’s Mojo Score has improved to 72.0, earning a Buy grade as of 18 June 2026, upgraded from a previous Hold rating. This upgrade signals enhanced confidence in the stock’s growth prospects and risk-reward profile. The Mojo grading system, widely followed by investors, incorporates fundamental, technical, and market sentiment factors, lending further credibility to the bullish stance.

Such an upgrade often attracts additional institutional interest, which can further fuel price appreciation and liquidity. The stock’s liquidity profile supports sizeable trade sizes, with a 2% average traded value equating to approximately ₹2.47 crores, ensuring ease of entry and exit for investors.

Investor Takeaways and Outlook

For investors, the current market signals from derivatives activity and price action suggest a favourable environment to consider Mankind Pharma as a growth candidate within the pharmaceuticals sector. The sustained increase in open interest and volume, coupled with the Mojo Score upgrade, indicate improving fundamentals and positive market sentiment.

However, investors should remain mindful of the stock’s proximity to its 52-week high, which may invite profit-taking or short-term volatility. Monitoring open interest trends and delivery volumes in the coming sessions will be crucial to confirm the durability of this bullish momentum.

Overall, Mankind Pharma’s recent market behaviour reflects a well-supported uptrend with growing investor conviction, making it a noteworthy contender for portfolios seeking exposure to mid-cap pharmaceutical growth stories.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today